What is Attune?
Attune Pharmaceuticals operates at the intersection of precision medicine and pharmacology, specializing in the development of orally-administered small-molecule therapeutics. The company is primarily focused on the modulation of serine proteases, a class of enzymes that play a critical role in various physiological processes. By targeting these specific pathways, Attune aims to address unmet medical needs in the rare disease sector. Its lead asset, ATN-249, represents a cornerstone of this strategy, demonstrating potential for once-a-day dosing and a favorable safety profile in early-stage evaluations. This focus on patient-centric drug design positions the company as a high-potential player in the pharmaceutical innovation ecosystem, particularly as it transitions from preclinical research toward more advanced clinical milestones.
How much funding has Attune raised?
Attune has raised a total of $23M across 1 funding round:
Series B
$23M
Series B (2019): $23M, investors not publicly disclosed
Key Investors in Attune
Attune
Undisclosed investor participating in the funding round.
What's next for Attune?
The recent capital allocation is expected to catalyze the advancement of the company's pipeline, specifically focusing on the transition of ATN-249 into more rigorous clinical trials. As Attune Pharmaceuticals scales its operations, the strategic deployment of these funds will likely prioritize regulatory engagement, manufacturing optimization, and the expansion of its research and development infrastructure. By leveraging this financial backing, the company is well-positioned to validate its therapeutic platform, potentially attracting further institutional interest as it moves closer to commercialization. The focus remains on delivering high-efficacy, well-tolerated treatments that address the complex challenges associated with rare disease management, ensuring long-term value creation for stakeholders and improved outcomes for patients globally.
See full Attune company page
